Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on September 12, 2025. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding a capital raise transaction announced on the same date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a disclosure of a financing event rather than a periodic financial report.
Material Changes and Events
- Capital Raise: The Company announced the pricing of a registered direct offering of common stock.
- Concurrent Placement: The offering includes a concurrent private placement of warrants.
- Disclosure: Details of the transaction are contained in a press release furnished as Exhibit 99.1, which is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies related to the offering. Investors must refer to the attached press release (Exhibit 99.1) for specific terms, pricing, and intended use of proceeds.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific price per share and total number of shares issued in the registered direct offering.
- Verify the terms of the concurrent private placement of warrants, including exercise price and expiration date.
- Confirm the total gross proceeds expected from the transaction and the stated use of proceeds.
- Check for any underwriting discounts or commissions associated with the offering.